F-star has a proprietary clinical pipeline of tetravalent mAb2 bispecifics that are designed to result in focused, potent and safe immune activation with easy to make molecules. F-star is also pursuing clinical trials of SB 11285, an intravenously administered, next generation STING agonist.
- FS118 - First-in-class LAG-3/PD-L1 mAb2 bispecific antibody
- FS120 - First-in-class CD137/OX40 mAb² dual agonist bispecific antibody
- FS222 - CD137/PD-L1 mAb² bispecific antibody
- SB 11285 - Second generation STING agonist for intravenous administration
F-star is also pursuing clinical trials of SB 11285, an intravenously administered next generation STING (STimulator of INterferon Genes) agonist.